Revising the Dosing of a Cancer Immunotherapeutic
The FDA has approved an alternative dosing schedule for the immune checkpoint inhibitor pembrolizumab. On April 28, 2020, the...
Progress Against Cancer
The FDA has approved an alternative dosing schedule for the immune checkpoint inhibitor pembrolizumab. On April 28, 2020, the...
The FDA has approved a combination of pembrolizumab and axitinib for treating certain patients with renal cell carcinoma, the...
The approval provides a third immunotherapy-based combination treatment for patients newly diagnosed with advanced renal cell carcinoma, the most...
The FDA has approved a combination of ipilimumab and nivolumab for treating intermediate- or poor-risk, previously untreated advanced renal...
In an early-phase trial, investigators study whether combining immunotherapies expands “tumor-specific immune activation.” A small phase Ib study of...
Researchers are seeking to understand why some patients do not respond to immunotherapeutics and to identify ways to ensure...
The U.S. Food and Drug Administration approval provides a new option for patients with the most common type of...
The newly approved therapeutic improved survival for patients with the most common type of kidney cancer compared with standard...
The U.S. Food and Drug Administration approval provides a new option for patients with the most common type of...
Two recent studies in AACR journals suggest that metabolic health problems are risk factors for some types of cancer....
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Now